Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $459000.0.

  • Corvus Pharmaceuticals' Amortizatization of Intangibles fell 1240.46% to $459000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 2923.98%. This contributed to the annual value of $1.1 million for FY2024, which is 2762.86% up from last year.
  • Corvus Pharmaceuticals' Amortizatization of Intangibles amounted to $459000.0 in Q3 2025, which was down 1240.46% from $334000.0 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $524000.0 during Q3 2024, with a 5-year trough of -$83000.0 in Q3 2022.
  • For the 4-year period, Corvus Pharmaceuticals' Amortizatization of Intangibles averaged around $219266.7, with its median value being $242000.0 (2024).
  • In the last 5 years, Corvus Pharmaceuticals' Amortizatization of Intangibles soared by 54500.0% in 2023 and then tumbled by 4280.3% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $158000.0 in 2022, then dropped by 19.62% to $127000.0 in 2023, then skyrocketed by 90.55% to $242000.0 in 2024, then soared by 89.67% to $459000.0 in 2025.
  • Its Amortizatization of Intangibles was $459000.0 in Q3 2025, compared to $334000.0 in Q2 2025 and $291000.0 in Q1 2025.